Nikhil C Munshi

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3441-9. 2006
  2. pmc Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo
    Masood A Shammas
    Department of Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Clin Cancer Res 14:4971-80. 2008
  3. doi request reprint The shaping and functional consequences of the dosage effect landscape in multiple myeloma
    Mehmet K Samur
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, Boston, MA 02215, USA
    BMC Genomics 14:672. 2013
  4. doi request reprint New strategies in the treatment of multiple myeloma
    Nikhil C Munshi
    Veterans Administration Boston Healthcare System, Boston, Massachusetts, USA
    Clin Cancer Res 19:3337-44. 2013
  5. pmc Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential
    Masood A Shammas
    Center for Swallowing and Motility Disorders, VA Boston Healthcare System, Boston, MA 02132, USA
    Mol Cancer 4:24. 2005
  6. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
  7. ncbi request reprint Identification of genes modulated in multiple myeloma using genetically identical twin samples
    Nikhil C Munshi
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston MA 02115, USA
    Blood 103:1799-806. 2004
  8. pmc Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
    Nikhil C Munshi
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:4696-700. 2011
  9. pmc CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
    Yu Tzu Tai
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:4309-18. 2009
  10. pmc Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:1656-63. 2007

Detail Information

Publications98

  1. pmc Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3441-9. 2006
    ..These data confirm the potential clinical benefit of combining HDAC inhibitors with proteasome inhibitors, and provide insight into the mechanisms of synergistic anti-MM activity of bortezomib in combination with LBH589...
  2. pmc Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo
    Masood A Shammas
    Department of Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Clin Cancer Res 14:4971-80. 2008
    ....
  3. doi request reprint The shaping and functional consequences of the dosage effect landscape in multiple myeloma
    Mehmet K Samur
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, Boston, MA 02215, USA
    BMC Genomics 14:672. 2013
    ....
  4. doi request reprint New strategies in the treatment of multiple myeloma
    Nikhil C Munshi
    Veterans Administration Boston Healthcare System, Boston, Massachusetts, USA
    Clin Cancer Res 19:3337-44. 2013
    ..We propose that eventually, molecularly informed multiagent combination therapies will be required to eliminate the multiple myeloma cell clone for long-term disease control...
  5. pmc Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential
    Masood A Shammas
    Center for Swallowing and Motility Disorders, VA Boston Healthcare System, Boston, MA 02132, USA
    Mol Cancer 4:24. 2005
    ..Chemical inhibitors of telomerase have been shown to reactivate telomere shortening and cause replicative senescence and apoptotic cell death of tumor cells while having little or no effect on normal diploid cells...
  6. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
    ..However, there is no software that can perform survival analysis using SNP array data or draw survival curves interactively for expression-based sample clusters...
  7. ncbi request reprint Identification of genes modulated in multiple myeloma using genetically identical twin samples
    Nikhil C Munshi
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston MA 02115, USA
    Blood 103:1799-806. 2004
    ..By identifying genes uniquely altered in MM cells compared with normal PCs in an identical genotypic background, the current study provides the framework to identify novel therapeutic targets...
  8. pmc Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
    Nikhil C Munshi
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:4696-700. 2011
    ..There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations...
  9. pmc CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
    Yu Tzu Tai
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:4309-18. 2009
    ..These studies provide direct evidence of the role of CS1 in myeloma pathogenesis, define molecular mechanisms regulating its effects, and further support novel therapies targeting CS1 in MM...
  10. pmc Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:1656-63. 2007
    ..Taken together, these results show that AZD6244 targets both MM cells and OCs in the BM microenvironment, providing the preclinical framework for clinical trials to improve patient outcome in MM...
  11. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
    ..Our studies therefore show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM...
  12. ncbi request reprint Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 24:3121-9. 2005
    ..Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS-341 resistance and improve patient outcome...
  13. ncbi request reprint Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 64:8746-53. 2004
    ..These findings have clinical significance, because identification of downstream apoptotic signaling after topoisomerase I inhibition will both elucidate mechanisms of resistance and optimize future combination chemotherapy against MM...
  14. ncbi request reprint The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2377-80. 2003
    ..These studies, therefore, provide the framework for clinical use of this agent in combination with conventional chemotherapy...
  15. ncbi request reprint Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 101:1530-4. 2003
    ..Inhibition of JNK activity abrogates PS-341-induced MM cell death. These studies identify molecular targets of PS-341 and provide the rationale for the development of second-generation, more targeted therapies...
  16. ncbi request reprint Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma
    Iris Breitkreutz
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 139:55-63. 2007
    ..The present study therefore provides a preclinical rationale for the evaluation of AZD6244 as a potential new therapy for patients with MM...
  17. pmc SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 106:706-12. 2005
    ..Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clinically relevant concentrations, targets Mcl-1, and can be synergistically combined with Dex...
  18. pmc Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1042-7. 2005
    ..Finally, combination studies of seliciclib with doxorubicin and bortezomib show in vitro synergism, providing the rationale for testing these drug combinations to improve patient outcome in MM...
  19. ncbi request reprint Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2846-52. 2004
    ..1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM...
  20. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
    ..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells...
  21. ncbi request reprint Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
    Toshiaki Hayashi
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 1:851-60. 2002
    ..These studies provide the rationale for clinical trials of As2O3, either alone or together with dexamethasone, to overcome classical drug resistance and improve outcome in patients with MM...
  22. ncbi request reprint Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 138:783-91. 2007
    ..These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM...
  23. ncbi request reprint NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 102:2615-22. 2003
    ..Finally, a study using NVP-LAQ824 in a preclinical murine myeloma model provides in vivo relevance to our in vitro studies. Taken together, these findings provide the framework for NVP-LAQ824 as a novel therapeutic in MM...
  24. ncbi request reprint Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 63:5850-8. 2003
    ..Moreover, they define the functional association of IGF-IR and beta1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM...
  25. pmc Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  26. pmc A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:3772-5. 2010
    ....
  27. pmc CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4341-51. 2009
    ..These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy...
  28. pmc In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Joseph M Negri
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 147:672-6. 2009
    ..Combinations with dexamethasone (Dex), doxorubicin (Doxo) and bortezomib showed no antagonism. Our study highlights the potential role of the tumour microenvironment in modulating the activity of this drug class...
  29. ncbi request reprint Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:4251-8. 2005
    ....
  30. ncbi request reprint CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2762-9. 2003
    ....
  31. ncbi request reprint Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:5898-906. 2005
    ..These results provide the preclinical rationale for clinical trials of CHIR-12.12 to improve patient outcome in multiple myeloma...
  32. pmc Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
    Kihyun Kim
    Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 149:537-49. 2010
    ..Our results therefore support clinical evaluation of AS703026, alone or in combination with other anti-MM agents, to improve patient outcome...
  33. ncbi request reprint In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells
    Paola Neri
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 134:37-44. 2006
    ..These data indicate that R-etodolac overcomes resistance to Dex in glucocorticoid-resistant MM cells, providing the framework for clinical trials of R-etodolac combined with Dex, to improve patient outcome in MM...
  34. ncbi request reprint Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
    Teru Hideshima
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Jerome Lipper Multiple Myeloma Center, 44 Binney Street, Boston, MA 02155, USA
    Oncogene 22:8386-93. 2003
    ..Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment...
  35. pmc Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
    ..Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105...
  36. doi request reprint Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:5216-25. 2008
    ..The profile of the anti-MM activity of Aplidin in our preclinical models provided the framework for its clinical testing in MM, which has already provided favorable preliminary results...
  37. pmc Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
    Makoto Hamasaki
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 105:4470-6. 2005
    ..These results, therefore, show that azaspirane both induces MM cell apoptosis and inhibits cytokine secretion in the BM milieu, providing the framework for clinical trials to improve patient outcome in MM...
  38. pmc Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
    Güllü Topal Görgün
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 121:2975-87. 2013
    ..Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy...
  39. pmc Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
    Yu Tzu Tai
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 120:1877-87. 2012
    ..Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM...
  40. doi request reprint Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
    Douglas W McMillin
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston Novartis Institutes for BioMedical Research, Cambridge, MA 02115, USA
    Br J Haematol 152:420-32. 2011
    ..These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM...
  41. ncbi request reprint Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model
    Paola Neri
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 13:5903-9. 2007
    ..It has been implicated in conferring a survival advantage to B-cell malignancies, including multiple myeloma (MM)...
  42. ncbi request reprint Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 66:6675-82. 2006
    ....
  43. pmc A clinically relevant SCID-hu in vivo model of human multiple myeloma
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and VA Boston Healthcare System, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 106:713-6. 2005
    ..We report that this model is highly reproducible and allows for evaluation of investigational drugs targeting IL-6-dependent MM cells in the human bone marrow (huBM) milieu...
  44. pmc Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
    Naoya Mimura
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 119:5772-81. 2012
    ..Taken together, our results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM...
  45. pmc Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 46:166-75. 2009
    ....
  46. ncbi request reprint Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 63:6187-94. 2003
    ....
  47. pmc Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:5228-36. 2009
    ..Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM...
  48. ncbi request reprint Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:18-21. 2003
    ..These studies suggest that NF-kappaB p65 plays a pivotal role in regulating telomerase by modulating its nuclear translocation...
  49. ncbi request reprint Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma
    Masood A Shammas
    Boston VA Health Care System, Boston, Massachusetts, USA
    Clin Cancer Res 10:770-6. 2004
    ..The aim of this study was to test the efficacy of telomestatin, an intramolecular G-quadruplex intercalating drug with specificity for telomeric sequences, as a potential therapeutic agent for multiple myeloma...
  50. ncbi request reprint Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:1346-58. 2002
    ..These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival...
  51. ncbi request reprint Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:11712-20. 2005
    ....
  52. ncbi request reprint Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 104:3688-96. 2004
    ....
  53. ncbi request reprint Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib
    Reshma Shringarpure
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 134:145-56. 2006
    ....
  54. ncbi request reprint Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
    Richard LeBlanc
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 103:1787-90. 2004
    ....
  55. pmc Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
    Masood A Shammas
    Veterans Administration Boston Health Care System, and Dana Farber Cancer Institute Harvard Medical School, 44 Binney Street, D1B25, Boston, MA 02115, USA
    Blood 108:2804-10. 2006
    ..Expression of related genes at the protein level were also confirmed by Western blot analysis. These data demonstrate potent and specific antimyeloma activity of EGCG and provide the rationale for its clinical evaluation...
  56. doi request reprint Significant biological role of sp1 transactivation in multiple myeloma
    Mariateresa Fulciniti
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 17:6500-9. 2011
    ..We here provide experimental and clinical evidence that Sp1 plays an important regulatory role in multiple myeloma (MM) cell growth and survival...
  57. pmc The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
    James J Driscoll
    Department of Research, Veterans Administration Boston Healthcare, West Roxbury, MA, USA
    Blood 115:2827-34. 2010
    ..The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies...
  58. pmc Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:5713-9. 2009
    ..This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortezomib in patients with relapsed or with relapsed and refractory MM...
  59. ncbi request reprint Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:5673-83. 2002
    ..Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1...
  60. doi request reprint Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 69:5835-42. 2009
    ..g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM...
  61. ncbi request reprint The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Boris Lin
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:5019-26. 2002
    ..The demonstrated anti-MM activity of PTK787, coupled with its antiangiogenic effects, provides the framework for clinical trials of this agent to overcome drug resistance and improve outcome in MM...
  62. ncbi request reprint beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells
    Deepak Gupta
    Jerome Lipper Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Exp Hematol 30:711-20. 2002
    ..1S); MM cell lines resistant to dexamethasone (MM.1R), melphalan (RPMI8226/LR5), doxorubicin (RPMI8226/DOX40), and mitoxantrone (RPMI8226/ MR20); and MM cells from patients (MM1-MM4)...
  63. ncbi request reprint p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Mayer 557, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 23:8766-76. 2004
    ..These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM...
  64. pmc A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma
    Mariateresa Fulciniti
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7144-52. 2009
    ....
  65. pmc MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:1285-90. 2008
    ..Together, these findings reveal that the alterations in the NKG2D pathway are associated with the progression from MGUS to MM and raise the possibility that anti-MICA monoclonal antibodies might prove therapeutic for these disorders...
  66. doi request reprint Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia
    Jenny Y Sun
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 11:152-6. 2011
    ..These results provided a framework for examining HDAC inhibitors as monotherapy, as well as combination therapy with bortezomib in WM...
  67. pmc Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
    Yu Tzu Tai
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 112:1329-37. 2008
    ..These results thus define the functional significance of CS1 in MM and provide the preclinical rationale for testing HuLuc63 in clinical trials, either alone or in combination...
  68. pmc Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney Street, Boston, MA 02115, USA
    Blood 107:4053-62. 2006
    ..Taken together, our data provide the rationale for clinical trials of perifosine to improve patient outcome in MM...
  69. ncbi request reprint Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells
    Klaus Podar
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:5794-801. 2003
    ..Taken together, this study identifies caveolin-1 and other structural membrane components as potential new therapeutic targets in multiple myeloma...
  70. ncbi request reprint Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, VA Boston Healthcare System and Harvard Medical School, Boston, MA 02115, USA
    Blood 104:4188-93. 2004
    ..These studies, therefore, provide the framework for clinical evaluation of mTOR inhibitors combined with IMiDs to improve patient outcome in MM...
  71. pmc Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 119:e131-8. 2012
    ..This study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for clinical development on the basis of their effect on antitumor immunity...
  72. ncbi request reprint Novel therapies in the treatment of multiple myeloma
    Jacob P Laubach
    Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:947-60. 2009
    ..In aggregate, the use of novel therapies in MM has been associated with substantial improvements in patient outcome...
  73. pmc Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
    Simona Blotta
    Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3276-84. 2009
    ..These findings demonstrate OFD1 as an important immune target and highlight its possible role in signal transduction and tumorigenesis in MGUS and MM...
  74. pmc A SCID-hu in vivo model of human Waldenström macroglobulinemia
    Pierfrancesco Tassone
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1341-5. 2005
    ..This model, therefore, recapitulates the in vivo biology of WM and allows the study of novel investigational drugs targeting WM cells in the huBM milieu...
  75. pmc Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
    Masood A Shammas
    Department of Medicine, VA Health Care System and Harvard Medical School Boston, MA, USA
    Blood 113:2290-7. 2009
    ..These data identify dysregulated HR activity as a key mediator of DNA instability and progression of MM, with potential as a therapeutic target...
  76. pmc Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
    ....
  77. ncbi request reprint Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
    Richard LeBlanc
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:4996-5000. 2002
    ....
  78. ncbi request reprint Cytokines modulate telomerase activity in a human multiple myeloma cell line
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:3876-82. 2002
    ..These studies therefore demonstrate that telomerase activity is associated with cell growth, survival, and drug resistance in MM cells...
  79. ncbi request reprint Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4525-30. 2002
    ..These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM...
  80. pmc Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib
    Melissa G Ooi
    Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7153-60. 2009
    ..The cis-imidazoline nutlin-3 can disrupt the p53-Hdm2 interaction and activate p53, inducing apoptosis in vitro in many malignancies, including multiple myeloma (MM)...
  81. ncbi request reprint Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor
    Masood A Shammas
    VA Boston Health Care System, Boston, MA, USA
    Gastroenterology 126:1337-46. 2004
    ..The purpose of this study was to evaluate effects of telomerase inhibition on BEAC...
  82. ncbi request reprint Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma
    Masood A Shammas
    Boston VA Health Care System, West Roxbury, MA, USA
    Mol Cancer Ther 2:825-33. 2003
    ..The aim of this study was to test the efficacy of telomerase inhibitor (TMPyP4 [tetra(N-methyl-4-pyridyl)-porphyrin chloride]; a G-quadruplex-intercalating porphyrin) as a potential therapeutic agent for multiple myeloma...
  83. pmc Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
    Roberto Bellucci
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:3945-50. 2005
    ..These results demonstrate that BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo...
  84. ncbi request reprint In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 64:4629-36. 2004
    ..Taken together, these data provide the framework for clinical trials of this agent to improve patient outcome in MM...
  85. ncbi request reprint Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 101:4055-62. 2003
    ....
  86. ncbi request reprint Telomerase inhibitors as anticancer therapy
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Curr Med Chem Anticancer Agents 2:567-75. 2002
    ..In this review, we will discuss the basic biology of telomeres and telomerase as a platform for the development of treatments based upon inhibition of telomerase activity...
  87. pmc Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
    Mariateresa Fulciniti
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:371-9. 2009
    ..These results confirm DKK1 as an important therapeutic target in myeloma and provide the rationale for clinical evaluation of BHQ880 to improve bone disease and to inhibit MM growth...
  88. doi request reprint Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:355-60. 2009
    ..We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent...
  89. pmc CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
    Allen W Ho
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 112:4683-9. 2008
    ..The results of these studies demonstrate a functional role for sCD27 in WM pathogenesis, along with its utility as a surrogate marker of disease and a target in the treatment of WM...
  90. pmc A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3458-64. 2006
    ..Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone...
  91. ncbi request reprint High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
    ..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable...
  92. ncbi request reprint Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    J Cell Biochem 101:950-68. 2007
    ....
  93. ncbi request reprint Tailoring treatment for multiple myeloma patients with relapsed and refractory disease
    Paul G Richardson
    Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology (Williston Park) 24:22-9. 2010
    ..Additional clinical challenges discussed in this article are renal dysfunction, extramedullary disease, and advanced bone disease. Finally, participation in clinical trials is especially encouraged in this patient population...
  94. ncbi request reprint The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies
    Constantine S Mitsiades
    Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1007-34, vii-viii. 2007
    ..This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior...
  95. ncbi request reprint The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street Boston, MA 02115, USA
    Eur J Cancer 42:1564-73. 2006
    ..g. lenalidomide), for the management of myeloma...
  96. ncbi request reprint FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 132:698-704. 2006
    ..Our studies therefore demonstrated in vitro anti-MM activity of FQPD and provide the rationale for its in vivo evaluation in animal models and derived clinical trials...
  97. ncbi request reprint Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
    Faith E Davies
    Academic Unit of Haematology and Oncology, Algernon Firth Bldg, School of Medicine, University of Leeds, Leeds, United Kingdom
    Blood 102:4504-11. 2003
    ..Understanding the molecular pathogenesis of MM by gene expression profiling has demonstrated sequential genetic changes from N to malignant PCs and highlighted important pathways involved in the transformation of MGUS to MM...
  98. ncbi request reprint Recent advances in the management of multiple myeloma
    Nikhil C Munshi
    Dana Farber Cancer Institute and Boston VA Medical Center, Harvard Medical School, MA 02115, USA
    Semin Hematol 41:21-6. 2004
    ..These innovative therapies for MM represent a new treatment paradigm, targeting tumor cells and their microenvironments to achieve greater tumor cytoreduction and potentially a cure...